Reckitt Benckiser Group (RB) Rating Reiterated by Barclays

Reckitt Benckiser Group (LON:RB)‘s stock had its “overweight” rating reaffirmed by Barclays in a research note issued to investors on Monday, Borsen Zeitung reports. They currently have a GBX 7,500 ($98.00) price objective on the stock. Barclays‘s target price indicates a potential upside of 27.68% from the stock’s current price.

A number of other analysts have also issued reports on the stock. Deutsche Bank set a GBX 8,000 ($104.53) target price on shares of Reckitt Benckiser Group and gave the company a “buy” rating in a research note on Thursday, April 11th. Jefferies Financial Group set a GBX 5,400 ($70.56) target price on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a research note on Thursday, April 11th. UBS Group reissued a “neutral” rating and set a GBX 6,400 ($83.63) target price on shares of Reckitt Benckiser Group in a research note on Wednesday, April 10th. Royal Bank of Canada reissued an “underperform” rating and set a GBX 5,300 ($69.25) target price on shares of Reckitt Benckiser Group in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Reckitt Benckiser Group in a research note on Monday, April 8th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of GBX 7,105 ($92.84).

Shares of RB opened at GBX 5,874 ($76.75) on Monday. The firm has a market cap of $41.58 billion and a PE ratio of 19.27. Reckitt Benckiser Group has a 12-month low of GBX 5,255 ($68.67) and a 12-month high of GBX 7,174 ($93.74). The company has a quick ratio of 0.47, a current ratio of 0.65 and a debt-to-equity ratio of 80.49.

In other news, insider Andrew R. J. Bonfield acquired 80 shares of the firm’s stock in a transaction that occurred on Thursday, February 28th. The stock was purchased at an average cost of GBX 5,760 ($75.26) per share, for a total transaction of £4,608 ($6,021.17). Also, insider Elane Stock acquired 1,860 shares of the firm’s stock in a transaction that occurred on Tuesday, February 19th. The stock was purchased at an average price of GBX 6,233 ($81.45) per share, with a total value of £115,933.80 ($151,488.04).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

See Also: What moving averages are used to define a golden cross?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit